

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sue MacLeman
Date of last notice	2 July 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Dalroar Pty Ltd (as trustee for the MacLeman Investment Trust)
Date of change	10 September 2021
No. of securities held prior to change	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (as trustee for the MacLeman Investment Trust): 137,462 Ordinary Shares 50,000 Options at \$0.4228 ea, expiring 8 December 2024 300,000 Options at \$0.40 ea, expiring 7 August 2025 41,665 Options exercisable at \$0.24 ea, expiring 29 June 2023
Class	Shares
Number acquired	Indirect – Dalroar Pty Ltd (as trustee for the MacLeman Investment Trust) 86,956 Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$10,126.43
No. of securities held after change	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (as trustee for the MacLeman Investment Trust): 224,418 Ordinary Shares 50,000 Options at \$0.4228 ea, expiring 8 December 2024 300,000 Options at \$0.40 ea, expiring 7 August 2025 41,665 Options exercisable at \$0.24 ea, expiring 29 June 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchased on market

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Not in a Closed Period
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.